Clinical Trial Update: Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of zanzalintinib and eribulin in patients with advanced liposarcoma and leiomyosarcoma; recruitment is ongoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Liposarcoma

Drugs mentioned

• Eribulin (eribulin mesilate)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Advanced Leiomyosarcoma, Adipocytic Sarcoma | Phase 1 | Status: RECRUITING